Induction Therapy for Thymoma

Usman Ahmad; James Huang

doi:10.1016/j.thorsurg.2016.04.011

Induction Therapy for Thymoma

Thorac Surg Clin. 2016 Aug;26(3):325-32. doi: 10.1016/j.thorsurg.2016.04.011.

Authors

Usman Ahmad¹, James Huang²

Affiliations

¹ Division of Thoracic Surgery, Department of Cardiothoracic Surgery, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, J4-1, Cleveland, OH 44195, USA. Electronic address: ahmadu@ccf.org.
² Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

PMID: 27427527
DOI: 10.1016/j.thorsurg.2016.04.011

Abstract

Thymomas are uncommon tumors that can present as locally advanced tumors in approximately 30% of the patients. Stage and complete resection are the strongest prognostic factors. For locally advanced tumors, induction treatment may improve the ability to achieve a complete resection. Combination treatment with cisplatin, doxorubicin, and cyclophosphamide is the most commonly used induction regimen. Similar rates of resectability are noted with the use of induction chemotherapy and chemoradiation therapy; however, more tumor necrosis is noted with the addition of radiation.

Keywords: Chemoradiation; Chemotherapy; Induction treatment; Neoadjuvant; Thymic tumors.

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Clinical Protocols*
Humans
Induction Chemotherapy / methods*
Thymoma / drug therapy*
Thymus Neoplasms / drug therapy*
Treatment Outcome

Substances

Antineoplastic Agents